Irisin is a myokine that is generated by cleavage of the membrane protein fibronectin type Ⅲ domain-containing protein 5(FNDC5) in response to physical exercise. Studies reveal that irisin/FNDC5 has neuroprotective f...Irisin is a myokine that is generated by cleavage of the membrane protein fibronectin type Ⅲ domain-containing protein 5(FNDC5) in response to physical exercise. Studies reveal that irisin/FNDC5 has neuroprotective functions against Alzheimer's disease, the most common form of dementia in the elderly, by improving cognitive function and reducing amyloid-β and tau pathologies as well as neuroinflammation in cell culture or animal models of Alzheimer's disease. Although current and ongoing studies on irisin/FNDC5 show promising results, further mechanistic studies are required to clarify its potential as a meaningful therapeutic target for alleviating Alzheimer's disease. We recently found that irisin treatment reduces amyloid-β pathology by increasing the activity/levels of amyloid-β-degrading enzyme neprilysin secreted from astrocytes. Herein, we present an overview of irisin/FNDC5's protective roles and mechanisms against Alzheimer's disease.展开更多
Irisin is a chief myokine released during physical activity and has garnered attention for its potential therapeutic effects on different metabolic and cardiovascular disorders.This review explores the intricate conne...Irisin is a chief myokine released during physical activity and has garnered attention for its potential therapeutic effects on different metabolic and cardiovascular disorders.This review explores the intricate connections between irisin,physical activity,sarcopenia,type 2 diabetes mellitus(T2DM),and cardiovascular complications.Experimental data suggests that through irisin release,physical activity positively influences muscle health,metabolic regulation,and cardiovascular function.In individuals with sarcopenia,characterized by progressive muscle mass and function loss,irisin plays a pivotal role in maintaining muscle integrity and function.Additionally,irisin’s beneficial effects on insulin sensitivity and glucose metabolism suggest its involvement in the pathophysiology of T2DM.The review will examine how irisin may modulate the development of cardiovascular complications,particularly in the context of diabetes and aging.Additionally,it will explore its potential as a therapeutic target for managing sarcopenia,T2DM,and cardiovascular complications,underscoring the importance of physical activity in mitigating these interconnected health challenges.Further research is needed to elucidate the precise mechanisms by which irisin mediates these effects and assess its clinical applicability in preventing and treating metabolic and cardiovascular disorders.展开更多
A diabetic skin ulcer model was established by combining streptozotocin(STZ)administration with fullthickness skin defect surgery to evaluate the changes in irisin levels during the healing process.The experiment was ...A diabetic skin ulcer model was established by combining streptozotocin(STZ)administration with fullthickness skin defect surgery to evaluate the changes in irisin levels during the healing process.The experiment was divided into 2 groups,with 6 mice in each group:the normal control group and the diabetic skin injury group.Compared with the normal group,the model injury group showed a significant increase in blood glucose(p<0.001),a significant decrease in healing rate(p<0.001),and a significant decrease in irisin levels(p<0.001)after 14 days.Irisin levels were positively correlated with blood glucose and positively correlated with wound healing rate.In conclusion,irisin may be a potential therapeutic target for the treatment of diabetic skin injury.展开更多
目的:观察心衰患者血清IRISIN水平变化规律,研究Irisin对心衰诊疗的临床价值。方法:连续收集西京医院心内科住院的心衰患者132例,根据NYHA心功能分级将患者分为三组,其中心功能Ⅱ级48例,Ⅲ级44例,Ⅳ级40例,同时选取心功能正常(左室射血...目的:观察心衰患者血清IRISIN水平变化规律,研究Irisin对心衰诊疗的临床价值。方法:连续收集西京医院心内科住院的心衰患者132例,根据NYHA心功能分级将患者分为三组,其中心功能Ⅱ级48例,Ⅲ级44例,Ⅳ级40例,同时选取心功能正常(左室射血分数LVEF>50%)的30例健康体检者为对照组。采用酶联免疫吸附试验(ELISA)检测患者血清中Irisin水平,根据Irisin水平分为低Irisin组和高Irisin组,比较两组间心衰的发生率,分析Irisin水平与心衰的关系。结果:①心衰组Irisin水平显著低于心功能正常组(6790±3628 ng/mL vs 12691±2272 ng/mL,P<0.01),且从Ⅱ级到Ⅳ级,逐渐降低;②心衰组LVEF值显著低于心功能正常组(45.7±8 vs 59.7±4.3,P<0.01),且从Ⅱ级到Ⅳ级,逐渐降低;③心衰组N末端B型利钠肽原(ProBNP)水平显著高于心功能正常组(2938±2795 pg/mL vs 184±151 pg/mL,P<0.01),且从Ⅱ级到Ⅳ级,逐渐升高;④低Irisin组心衰发生率明显高于高Irisin组(92.6%vs47.5%,P<0.01);⑤单因素相关分析显示:血清Irisin水平与左室射血分数呈正相关(r=0.694,P<0.05),与proBNP呈负相关(r=-0.45,P<0.05);结论:心衰患者血清Irisin水平降低,而且随着心功能的恶化显著降低,心衰患者血清Irisin水平与心衰程度有一定的相关性。展开更多
基金supported by Cure Alzheimer’s Fund(to RET and SHC)JPB Foundation(to RET),and R56AG072054(to SHC)。
文摘Irisin is a myokine that is generated by cleavage of the membrane protein fibronectin type Ⅲ domain-containing protein 5(FNDC5) in response to physical exercise. Studies reveal that irisin/FNDC5 has neuroprotective functions against Alzheimer's disease, the most common form of dementia in the elderly, by improving cognitive function and reducing amyloid-β and tau pathologies as well as neuroinflammation in cell culture or animal models of Alzheimer's disease. Although current and ongoing studies on irisin/FNDC5 show promising results, further mechanistic studies are required to clarify its potential as a meaningful therapeutic target for alleviating Alzheimer's disease. We recently found that irisin treatment reduces amyloid-β pathology by increasing the activity/levels of amyloid-β-degrading enzyme neprilysin secreted from astrocytes. Herein, we present an overview of irisin/FNDC5's protective roles and mechanisms against Alzheimer's disease.
文摘Irisin is a chief myokine released during physical activity and has garnered attention for its potential therapeutic effects on different metabolic and cardiovascular disorders.This review explores the intricate connections between irisin,physical activity,sarcopenia,type 2 diabetes mellitus(T2DM),and cardiovascular complications.Experimental data suggests that through irisin release,physical activity positively influences muscle health,metabolic regulation,and cardiovascular function.In individuals with sarcopenia,characterized by progressive muscle mass and function loss,irisin plays a pivotal role in maintaining muscle integrity and function.Additionally,irisin’s beneficial effects on insulin sensitivity and glucose metabolism suggest its involvement in the pathophysiology of T2DM.The review will examine how irisin may modulate the development of cardiovascular complications,particularly in the context of diabetes and aging.Additionally,it will explore its potential as a therapeutic target for managing sarcopenia,T2DM,and cardiovascular complications,underscoring the importance of physical activity in mitigating these interconnected health challenges.Further research is needed to elucidate the precise mechanisms by which irisin mediates these effects and assess its clinical applicability in preventing and treating metabolic and cardiovascular disorders.
基金Ningbo Yinzhou District Agricultural and Social Development Technology Plan Project for Jiang Xi(Project No.:2022AS036)Zhejiang Provincial Science Foundation of China,Yu Xuefeng(Project No.:LTGY24H150003)。
文摘A diabetic skin ulcer model was established by combining streptozotocin(STZ)administration with fullthickness skin defect surgery to evaluate the changes in irisin levels during the healing process.The experiment was divided into 2 groups,with 6 mice in each group:the normal control group and the diabetic skin injury group.Compared with the normal group,the model injury group showed a significant increase in blood glucose(p<0.001),a significant decrease in healing rate(p<0.001),and a significant decrease in irisin levels(p<0.001)after 14 days.Irisin levels were positively correlated with blood glucose and positively correlated with wound healing rate.In conclusion,irisin may be a potential therapeutic target for the treatment of diabetic skin injury.
文摘目的:观察心衰患者血清IRISIN水平变化规律,研究Irisin对心衰诊疗的临床价值。方法:连续收集西京医院心内科住院的心衰患者132例,根据NYHA心功能分级将患者分为三组,其中心功能Ⅱ级48例,Ⅲ级44例,Ⅳ级40例,同时选取心功能正常(左室射血分数LVEF>50%)的30例健康体检者为对照组。采用酶联免疫吸附试验(ELISA)检测患者血清中Irisin水平,根据Irisin水平分为低Irisin组和高Irisin组,比较两组间心衰的发生率,分析Irisin水平与心衰的关系。结果:①心衰组Irisin水平显著低于心功能正常组(6790±3628 ng/mL vs 12691±2272 ng/mL,P<0.01),且从Ⅱ级到Ⅳ级,逐渐降低;②心衰组LVEF值显著低于心功能正常组(45.7±8 vs 59.7±4.3,P<0.01),且从Ⅱ级到Ⅳ级,逐渐降低;③心衰组N末端B型利钠肽原(ProBNP)水平显著高于心功能正常组(2938±2795 pg/mL vs 184±151 pg/mL,P<0.01),且从Ⅱ级到Ⅳ级,逐渐升高;④低Irisin组心衰发生率明显高于高Irisin组(92.6%vs47.5%,P<0.01);⑤单因素相关分析显示:血清Irisin水平与左室射血分数呈正相关(r=0.694,P<0.05),与proBNP呈负相关(r=-0.45,P<0.05);结论:心衰患者血清Irisin水平降低,而且随着心功能的恶化显著降低,心衰患者血清Irisin水平与心衰程度有一定的相关性。
